Life Sciences Transactions

At Baker McKenzie, we have formed a Global Healthcare & Life Sciences Group that leverages our extensive expertise across all practice areas and offices to provide a focused industry offering to our clients. Our Top 50 Healthcare & Life Sciences clients include 24 of the pharmaceutical and medical device companies ranked in the 2024 Global Fortune 500. This track record underscores our ability to deliver exceptional service and results to some of the most prominent players in the industry, reinforcing our position as a trusted partner in life sciences transactions.

Our team is adept at handling all transactional needs, from small acquisitions of early-stage products to high-value transactions and complex global multijurisdictional projects. 

In the ever-changing market landscape, businesses face growing competition, cost pressures, and the challenge of achieving sustainable growth. Our life sciences transactions team offers well-rounded advice across 46 jurisdictions, providing clients with a keen understanding of the transactional landscape, industry trends, and regulatory outlook. This holistic perspective enables us to guide our clients through the complexities of the market, helping them navigate challenges and seize opportunities for growth.

Explore more below.

Collaborations and Licensing

• Complex multinational collaborations
• Joint ventures
• Commercialization agreements
• Co-promotion agreements
• Research and development agreements
• Evaluation and option agreements

M&A

• Product acquisitions and divestitures
• Company sales and acquisitions
• Business unit spinoffs
• Post-acquisition integration

Financings

• Equity financing
• Royalty monetization
• Development funding agreements

Operational Agreements

• Manufacturing and supply agreements
• Distribution agreements
• Services agreements
• University and other nonprofit agreements